Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK.

N Engl J Med. 2005 Jun 16;352(24):2499-507.

2.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
3.

Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007571. doi: 10.1002/14651858.CD007571. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD007571.

PMID:
19160337
4.

LDP-02 (Millenium).

Marshall JK.

Curr Opin Investig Drugs. 2001 Apr;2(4):502-4. Review.

PMID:
11566006
5.

Vedolizumab for the treatment of ulcerative colitis.

Rietdijk ST, D'Haens GR.

Expert Rev Clin Pharmacol. 2014 Jul;7(4):423-30. doi: 10.1586/17512433.2014.911084. Epub 2014 May 6. Review.

PMID:
24802046
6.

[The management of ulcerative colitis in remission stage and the strategies for colorectal cancer surveillance in ulcerative colitis].

Takahashi S, Kinouchi Y, Endo K, Shiga H, Shimosegawa T.

Nihon Shokakibyo Gakkai Zasshi. 2011 Dec;108(12):1983-95. Review. Japanese. No abstract available.

PMID:
22139485
7.

The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.

Fiorino G, Gilardi D, Danese S.

Therap Adv Gastroenterol. 2016 Jul;9(4):503-12. doi: 10.1177/1756283X16647935. Epub 2016 May 19. Review.

Supplemental Content

Support Center